|
AU711057B2
(en)
*
|
1995-05-30 |
1999-10-07 |
Aventis Pharma S.A. |
2-azabicyclo(2,2,1)heptane derivatives, their preparation and their application
|
|
TW528755B
(en)
|
1996-12-24 |
2003-04-21 |
Glaxo Group Ltd |
2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
|
|
JP3861413B2
(ja)
*
|
1997-11-05 |
2006-12-20 |
ソニー株式会社 |
情報配信システム、情報処理端末装置、携帯端末装置
|
|
YU44900A
(sh)
|
1998-01-31 |
2003-01-31 |
Glaxo Group Limited |
Derivati 2-(purin-9-il)tetrahidrofuran-3,4-diola
|
|
UA62996C2
(en)
*
|
1998-02-26 |
2004-01-15 |
Aventic Pharmaceuticals Inc |
6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino]purines
|
|
US6413974B1
(en)
|
1998-02-26 |
2002-07-02 |
Aventis Pharmaceuticals Inc. |
6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
|
|
US6479487B1
(en)
|
1998-02-26 |
2002-11-12 |
Aventis Pharmaceuticals Inc. |
6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
|
|
US6878716B1
(en)
|
1998-06-02 |
2005-04-12 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptor and uses thereof
|
|
IL139787A0
(en)
|
1998-06-02 |
2002-02-10 |
Osi Pharm Inc |
PYRROLO [2, 3d] PYRIMIDINE COMPOSITIONS AND THEIR USE
|
|
US6686366B1
(en)
|
1998-06-02 |
2004-02-03 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
|
EA200001224A1
(ru)
*
|
1998-06-23 |
2001-08-27 |
Глаксо Груп Лимитед |
Производные 2-(пурин-9-ил)-тетрагидрофуран-3,4-диола
|
|
GB9813565D0
(en)
*
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB9813535D0
(en)
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB9813554D0
(en)
*
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
|
GB9813540D0
(en)
*
|
1998-06-23 |
1998-08-19 |
Glaxo Group Ltd |
Chemical compounds
|
|
RU2258071C2
(ru)
*
|
1999-05-24 |
2005-08-10 |
Юниверсити Оф Вирджиния Пэйтент Фаундейшн |
Производные 2-алкиниладенозина для борьбы с воспалительной реакцией
|
|
US6664252B2
(en)
|
1999-12-02 |
2003-12-16 |
Osi Pharmaceuticals, Inc. |
4-aminopyrrolo[2,3-d]pyrimidine compounds specific to adenosine A2a receptor and uses thereof
|
|
US7160890B2
(en)
|
1999-12-02 |
2007-01-09 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
|
US6680322B2
(en)
|
1999-12-02 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
|
US7115589B2
(en)
|
1999-12-17 |
2006-10-03 |
Ariad Pharmaceuticals, Inc. |
Purine derivatives
|
|
DK2223922T3
(en)
*
|
2000-04-25 |
2016-06-06 |
Icos Corp |
Inhibitors of HUMANPHOSPHATIDYL-inositol 3-KINASEDELTA
|
|
EP1939203B1
(en)
*
|
2000-04-25 |
2014-11-19 |
ICOS Corporation |
Inhibitors of human phosphatidyl-inositol 3-kinase delta isoform
|
|
US6667300B2
(en)
|
2000-04-25 |
2003-12-23 |
Icos Corporation |
Inhibitors of human phosphatidylinositol 3-kinase delta
|
|
US6861524B2
(en)
|
2000-10-31 |
2005-03-01 |
Aventis Pharmaceuticals Inc. |
Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
|
|
US6680324B2
(en)
|
2000-12-01 |
2004-01-20 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A1 receptors and uses thereof
|
|
US6673802B2
(en)
|
2000-12-01 |
2004-01-06 |
Osi Pharmaceuticals, Inc. |
Compounds specific to adenosine A3 receptor and uses thereof
|
|
WO2002088079A2
(en)
*
|
2001-05-01 |
2002-11-07 |
Bristol-Myers Squibb Company |
Dual inhibitors of pde 7 and pde 4
|
|
PE20030008A1
(es)
*
|
2001-06-19 |
2003-01-22 |
Bristol Myers Squibb Co |
Inhibidores duales de pde 7 y pde 4
|
|
US7745420B2
(en)
*
|
2001-07-06 |
2010-06-29 |
Topigen Pharmaceutique, Inc. |
Methods for increasing in vivo efficacy of oligonucleotides and inhibiting inflammation in mammals
|
|
KR100937620B1
(ko)
*
|
2001-11-09 |
2010-01-20 |
씨브이 쎄러퓨틱스, 인코포레이티드 |
A2b 아데노신 수용체 길항제
|
|
US7321033B2
(en)
|
2001-11-27 |
2008-01-22 |
Anadys Pharmaceuticals, Inc. |
3-B-D-ribofuranosylthiazolo [4,5-d] pyrimidine nucleosides and uses thereof
|
|
CN1300165C
(zh)
|
2001-11-27 |
2007-02-14 |
安那迪斯药品股份有限公司 |
3-β-呋喃核糖基噻唑并[4,5-d]嘧啶核苷及其应用
|
|
DE60234118D1
(de)
|
2001-11-30 |
2009-12-03 |
Osi Pharm Inc |
Verbindungen, die für Adenosin A1 und A3 Rezeptoren spezifisch sind, und deren Anwendungen
|
|
BR0215202A
(pt)
|
2001-12-20 |
2004-10-13 |
Osi Pharm Inc |
Compostos antagonistas seletivos a2b de pirimidina, sua sìntese e uso
|
|
US20030229067A1
(en)
|
2001-12-20 |
2003-12-11 |
Arlindo Castelhano |
Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use
|
|
ES2237234B1
(es)
*
|
2002-08-02 |
2006-11-01 |
Universidad De Oviedo |
Preparacion de (+) y (-)-trans-ciclopentano-1,2-diamina.
|
|
WO2004016635A2
(en)
*
|
2002-08-15 |
2004-02-26 |
Cv Therapeutics, Inc. |
Partial and full agonists of a1 adenosine receptors
|
|
AR044519A1
(es)
|
2003-05-02 |
2005-09-14 |
Novartis Ag |
Derivados de piridin-tiazol amina y de pirimidin-tiazol amina
|
|
GB0328319D0
(en)
*
|
2003-12-05 |
2004-01-07 |
Cambridge Biotechnology Ltd |
Improved synthesis of 2-substituted adenosines
|
|
GB0401334D0
(en)
|
2004-01-21 |
2004-02-25 |
Novartis Ag |
Organic compounds
|
|
EP1761540B1
(en)
|
2004-05-13 |
2016-09-28 |
Icos Corporation |
Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
|
|
GB0411056D0
(en)
|
2004-05-18 |
2004-06-23 |
Novartis Ag |
Organic compounds
|
|
PE20060272A1
(es)
|
2004-05-24 |
2006-05-22 |
Glaxo Group Ltd |
(2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a
|
|
US7423144B2
(en)
*
|
2004-05-26 |
2008-09-09 |
Inotek Pharmaceuticals Corporation |
Purine Derivatives as adenosine A1 receptor agonists and methods of use thereof
|
|
FR2874014B1
(fr)
*
|
2004-08-03 |
2010-05-14 |
Univ Paris Descartes |
Analogues d'aminoglycosides, leur utilisation et leur synthese
|
|
MX2007005083A
(es)
*
|
2004-10-29 |
2007-10-03 |
Topigen Pharmaceuticals Inc |
Oligonucleotidos antisentido para tratar alergias y proliferacion celular neoplastica.
|
|
GB0424284D0
(en)
|
2004-11-02 |
2004-12-01 |
Novartis Ag |
Organic compounds
|
|
GB0426164D0
(en)
|
2004-11-29 |
2004-12-29 |
Novartis Ag |
Organic compounds
|
|
JP5303149B2
(ja)
|
2004-12-17 |
2013-10-02 |
アナディス ファーマシューティカルズ インク |
3,5−二置換及び3,5,7−三置換−3H−オキサゾロ及び3H−チアゾロ[4,5−d]ピリミジン−2−オン化合物及びそのプロドラッグ
|
|
GB0500785D0
(en)
*
|
2005-01-14 |
2005-02-23 |
Novartis Ag |
Organic compounds
|
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
|
GB0514809D0
(en)
|
2005-07-19 |
2005-08-24 |
Glaxo Group Ltd |
Compounds
|
|
US7910708B2
(en)
|
2005-10-21 |
2011-03-22 |
Novartis Ag |
Anti-IL13 human antibodies
|
|
DE602006015700D1
(de)
|
2005-11-21 |
2010-09-02 |
Anadys Pharmaceuticals Inc |
Neues verfahren zur herstellung von 5-amino-3h-thiazoloä4,5-düpyrimidin-2-on
|
|
GB0601951D0
(en)
|
2006-01-31 |
2006-03-15 |
Novartis Ag |
Organic compounds
|
|
TWI418561B
(zh)
|
2006-06-22 |
2013-12-11 |
Anadys Pharmaceuticals Inc |
5-胺基-3-(3’-去氧-β-D-核糖呋喃糖基(ribofuranosyl))-噻唑并〔4,5-d〕嘧啶-2,7-二酮之前藥
|
|
JP5225991B2
(ja)
|
2006-07-18 |
2013-07-03 |
アナディス ファーマシューティカルズ インク |
チアゾロ[4,5−d]ピリミジンのカーボネート及びカルバメートプロドラッグ
|
|
KR20090073121A
(ko)
|
2006-09-29 |
2009-07-02 |
노파르티스 아게 |
Pi3k 지질 키나제 억제제로서의 피라졸로피리미딘
|
|
KR20090075714A
(ko)
|
2006-10-30 |
2009-07-08 |
노파르티스 아게 |
소염제로서의 헤테로시클릭 화합물
|
|
WO2009032057A2
(en)
|
2007-08-29 |
2009-03-12 |
Adam Lubin |
Method for the selective therapy of disease
|
|
EP2231642B1
(en)
|
2008-01-11 |
2013-10-23 |
Novartis AG |
Pyrimidines as kinase inhibitors
|
|
ES2331867B1
(es)
*
|
2008-07-17 |
2010-10-27 |
Entrechem, S.L. |
Sintesis enzimatica de derivados enantiomericamente enriquecidos de trans-ciclopentano- 1,2-diaminas.
|
|
US9492449B2
(en)
|
2008-11-13 |
2016-11-15 |
Gilead Calistoga Llc |
Therapies for hematologic malignancies
|
|
KR20160091440A
(ko)
|
2008-11-13 |
2016-08-02 |
길리아드 칼리스토가 엘엘씨 |
혈액 종양에 대한 요법
|
|
PL2391366T3
(pl)
|
2009-01-29 |
2013-04-30 |
Novartis Ag |
Podstawione benzimidazole do leczenia gwiaździaków
|
|
CA2756347A1
(en)
|
2009-03-24 |
2010-09-30 |
Gilead Calistoga Llc |
Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
|
|
SG175259A1
(en)
|
2009-04-20 |
2011-11-28 |
Gilead Calistoga Llc |
Methods of treatment for solid tumors
|
|
AU2010276160A1
(en)
|
2009-07-21 |
2012-02-09 |
Gilead Calistoga Llc |
Treatment of liver disorders with PI3K inhibitors
|
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
|
EA201200260A1
(ru)
|
2009-08-12 |
2012-09-28 |
Новартис Аг |
Гетероциклические гидразоны и их применение для лечения рака и воспаления
|
|
MY162604A
(en)
|
2009-08-17 |
2017-06-30 |
Intellikine Llc |
Heterocyclic compounds and uses thereof
|
|
MX2012002179A
(es)
|
2009-08-20 |
2012-03-16 |
Novartis Ag |
Compuestos heterociclicos de oxima.
|
|
WO2011086053A1
(en)
|
2010-01-12 |
2011-07-21 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof
|
|
US8637516B2
(en)
|
2010-09-09 |
2014-01-28 |
Irm Llc |
Compounds and compositions as TRK inhibitors
|
|
WO2012034095A1
(en)
|
2010-09-09 |
2012-03-15 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
JP2014505088A
(ja)
|
2011-02-10 |
2014-02-27 |
ノバルティス アーゲー |
C−METチロシンキナーゼ阻害剤としての[1,2,4]トリアゾロ[4,3−b]ピリダジン化合物
|
|
EP2678016B1
(en)
|
2011-02-23 |
2016-08-10 |
Intellikine, LLC |
Heterocyclic compounds and uses thereof
|
|
AU2012220572A1
(en)
|
2011-02-25 |
2013-08-29 |
Irm Llc |
Compounds and compositions as trk inhibitors
|
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
|
UY34329A
(es)
|
2011-09-15 |
2013-04-30 |
Novartis Ag |
Compuestos de triazolopiridina
|
|
US20130209543A1
(en)
|
2011-11-23 |
2013-08-15 |
Intellikine Llc |
Enhanced treatment regimens using mtor inhibitors
|
|
EA025407B1
(ru)
|
2012-03-05 |
2016-12-30 |
Джилид Калистога Ллс |
Полиморфная форма i (s)-2-(1-(9h-пурин-6-иламино)пропил)-5-фтор-3-фенилхиназолин-4(3h)-она
|
|
CN110507654A
(zh)
|
2012-04-03 |
2019-11-29 |
诺华有限公司 |
有酪氨酸激酶抑制剂的组合产品和其应用
|
|
CA2893843C
(en)
|
2012-12-21 |
2018-09-04 |
Gilead Sciences, Inc. |
Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
|
|
EP2968340A4
(en)
|
2013-03-15 |
2016-08-10 |
Intellikine Llc |
COMBINING KINASE INHIBITORS AND USES THEREOF
|
|
DK3019503T3
(da)
|
2013-07-12 |
2017-11-20 |
Gilead Sciences Inc |
Polycykliske-carbamoylpyridon-forbindelser og anvendelse deraf til behandling af hiv-infektioner
|
|
NO2865735T3
(forum.php)
|
2013-07-12 |
2018-07-21 |
|
|
|
WO2015084804A1
(en)
|
2013-12-03 |
2015-06-11 |
Novartis Ag |
Combination of mdm2 inhibitor and braf inhibitor and their use
|
|
WO2015095605A1
(en)
|
2013-12-20 |
2015-06-25 |
Gilead Calistoga Llc |
Polymorphic forms of a hydrochloride salt of (s) -2-(9h-purin-6-ylamino) propyl) -5-fluoro-3-phenylquinazolin-4 (3h) -one
|
|
NZ720867A
(en)
|
2013-12-20 |
2018-01-26 |
Gilead Calistoga Llc |
Process methods for phosphatidylinositol 3-kinase inhibitors
|
|
JP6455995B2
(ja)
|
2014-06-13 |
2019-01-23 |
ギリアード サイエンシーズ, インコーポレイテッド |
ホスファチジルイノシトール3−キナーゼ阻害剤
|
|
NO2717902T3
(forum.php)
|
2014-06-20 |
2018-06-23 |
|
|
|
TWI677489B
(zh)
|
2014-06-20 |
2019-11-21 |
美商基利科學股份有限公司 |
多環型胺甲醯基吡啶酮化合物之合成
|
|
TW201613936A
(en)
|
2014-06-20 |
2016-04-16 |
Gilead Sciences Inc |
Crystalline forms of(2R,5S,13aR)-8-hydroxy-7,9-dioxo-n-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1',2':4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
|
|
WO2016011658A1
(en)
|
2014-07-25 |
2016-01-28 |
Novartis Ag |
Combination therapy
|
|
KR20170036037A
(ko)
|
2014-07-31 |
2017-03-31 |
노파르티스 아게 |
조합 요법
|
|
WO2018030184A1
(ja)
*
|
2016-08-10 |
2018-02-15 |
株式会社スリーボンド |
エポキシ樹脂組成物およびこれを含む導電性接着剤
|
|
CN106632339B
(zh)
*
|
2016-12-16 |
2018-11-27 |
温州医科大学 |
一种6-取代-9h-嘌呤类衍生物及其制备方法和应用
|
|
EP3749697A4
(en)
|
2018-02-05 |
2021-11-03 |
Bio-Rad Laboratories, Inc. |
CHROMATOGRAPHY RESIN WITH LIGAND MIXED MODE ANIONIC / HYDROPHOBIC EXCHANGE
|
|
TW202140550A
(zh)
|
2020-01-29 |
2021-11-01 |
瑞士商諾華公司 |
使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
|
|
CN119798352B
(zh)
*
|
2024-01-15 |
2025-11-11 |
中国医学科学院药物研究所 |
化合物yzg-331的晶型及其制备方法
|